Home
Sitemap
中文版
English
Drugs
Medical Devices
Consultation Services
Health Technology Assessment
International Cooperation
About Us
FAQ
Drugs
Home
FAQ
Drugs
All
Class
Technical Dossier Review of Drugs
New Drug Application (NDA)
Investigational New Drug Application(IND)
Application of Bridging Study Evaluation (BSE)
Active Pharmaceutical Ingredient (API)
Abbreviated New Drug Application (ANDA)
Drug Substance
CIRB
Botanical drug
Instruction Drugs
Postapproval Changes
Investigational New Drug Application(IND)
No.
Class
Title
21
Drug Substance
When submitting a DMF application, is it acceptable to submit only a batch manufacturing record and not performing the process validations using three industrial batches?
22
Drug Substance
What is the definition of an API mix? What information must be provided while submitting a DMF for API mix?
23
Drug Substance
If a potential genotoxic impurity is formed or introduced prior to the final step of the API manufacturing process, under what conditions can one waive routine control of the potential genotoxic impurity in the drug substance specification?
24
Drug Substance
If a new drug substance is not yet listed in any pharmacopoeial monograph, how does one establish the acceptance criterion for total (organic) impurities in the drug substance specification?
25
Drug Substance
Should the information of reference standards for all impurities listed in the specification of drug substance be provided in section 3.2.S.5 Reference Standards or Materials?
26
Drug Substance
What information should be provided when there are multiple sources for a starting material?
27
Drug Substance
What information on impurities in the drug substance should be included in CTD Section 3.2.S.3.2 when submitting a DMF/API application?
28
Drug Substance
For starting materials that are not commercially available, what information should be provided on the production of starting materials?
29
Drug Substance
According to section 3.2.S.2.2 in the DMF Technical Document Checklist annexed to the public promulgation no. DOH 1021401257, information such as "microorganism characterization" and "seed-lot system" should be provided if a drug substance is derived from fermentation process. What specific information should be provided for "microorganism characterization" and "seed-lot system"?
30
Drug Substance
If metal catalysts are used in the manufacturing process of the drug substance, what data should be provided in order to waive routine control of such metal (elemental) impurities?
Page
Page:
3/24
‧ Total:
233
1
|
2
|
3
|
4
|
5
|
6
|
7
|
8
|
Drugs
Medical Devices
Consultation Services
Health Technology Assessment
International Cooperation